How IFU translation errors void manufacturer liability protection. Clinical-background translators, ISO 15223 symbol requirements, and native-language review.
- The IFU is a safety control
- Where exposure comes from
- What reduces it
The IFU is a safety control
Instructions for use are not documentation about a device; for many risks they are the control that mitigates them. Warnings, contraindications and handling steps are the mechanism by which a residual risk is managed.
When the translated version weakens a warning or blurs a contraindication, the control is weaker in that market than the risk file assumes — while the risk file still claims it is in place.
Where exposure comes from
If a user in a given market received instructions that did not convey what the source conveyed, the adequacy of the warning in that market can be questioned. That is a materially worse position than a translation dispute.
We are describing exposure, not a legal outcome — liability depends on jurisdiction and facts. Treat this as a reason to involve your legal and quality functions in labelling translation, not as legal advice.
What reduces it
Reviewers with clinical or biomedical background rather than general linguists. Terminology locked against your approved labelling. Consistent handling of symbols and their accompanying text. A documented review step you can point to.
None of this is exotic. The failures we see come from IFU content being treated as routine documentation and routed accordingly.